Rockwell Medical, Inc. — FY 2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016; filed March 15, 2017. Rockwell is a renal-care products and biopharmaceutical company. More than 95% of 2016 revenue came from hemodialysis concentrates; sales of Triferic and other drug products were not material.
Financial performance and liquidity
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Revenue | $53.3 million | $55.4 million |
| Gross profit / margin | $6.8 million / 12.7% | $8.9 million / 16.1% |
| Operating loss | $20.2 million | $15.1 million |
| Net loss / diluted loss per share | $19.8 million / $0.39 | $14.4 million / $0.29 |
| Cash used in operations | $12.5 million | $16.2 million |
| Cash and cash equivalents | $17.2 million | $31.2 million |
| Available-for-sale investments | $40.8 million | $39.5 million |
| Current assets / current liabilities | $78.5 million / $10.1 million | $84.6 million / $8.1 million |
| Long-term debt | None | None |
Working capital was $68.4 million at year-end, compared with $76.5 million a year earlier. Cash plus investments totaled approximately $57.9 million, down from $70.7 million. Capital expenditures were $0.4 million. Operating cash use included a $6.1 million inventory increase.
Fourth-quarter 2016 revenue was $13.4 million and net loss was $5.1 million, versus $14.1 million and a $5.8 million loss in fourth-quarter 2015.
Material changes versus prior year
- Revenue declined 3.7%, mainly because third-party contract manufacturing sales fell $1.6 million after a contract ended and international concentrate revenue decreased $0.6 million; domestic concentrate revenue was roughly flat.
- Gross margin contracted to 12.7% from 16.1%. Management cited drug-product operating, regulatory, material and inventory costs, lower contract-manufacturing and international volumes, and $0.2 million of value-added taxes related to the China license payment.
- SG&A rose to $21.1 million from $19.1 million, including higher equity-compensation and legal costs. Research and development increased to $5.8 million from $5.0 million.
- Loss widened despite higher net interest income; the company had no debt or interest expense in 2016. Cash balances declined as operating losses and inventory investment continued.
Outlook, risks and unusual items
- Triferic: FDA-approved for adult hemodialysis patients, but U.S. adoption and revenue remained limited. CMS included it in the dialysis bundle; Rockwell was seeking separate transitional add-on reimbursement. Management expected that status to accelerate uptake, but acknowledged there was no assurance it would be granted or when. The company held more than $10 million of Triferic inventory, including active ingredient with a generally three-year shelf life, creating potential write-down risk if sales lag.
- Calcitriol: Commercial launch was delayed because manufacturing-process changes required FDA review through a Prior Approval Supplement. Management anticipated possible approval and availability in the second half of 2017, subject to approval and adequate conforming inventory.
- International licensing: The China agreement provided a $4 million upfront payment, recognized over the agreement term, with up to $35 million in potential milestones and sales-based earnings. A Middle East agreement included a $1 million licensing fee, royalties and minimum purchase commitments; sales depend on regulatory approvals. Rockwell retains manufacturing responsibilities.
- Baxter dispute: Baxter initiated arbitration in September 2016, alleging breaches and seeking termination rights, up to $10 million of upfront-fee recovery, an injunction regarding a proposed West Coast facility and unspecified damages. Rockwell denied the allegations and counterclaimed over receivables and the facility fee. The parties also disputed minimum-purchase compliance and exclusivity. The arbitration was expected to conclude in the third quarter of 2017; its outcome could affect distribution, revenue, cash flows and possible fee refunds.
- Customer concentration: DaVita accounted for 52% of 2016 sales; Baxter represented approximately 24% of sales directly. Loss of major customers or disruption to Baxter distribution could materially affect results.
- Management stated it believed liquidity was adequate for planned operations and development spending, and expected positive operating cash flow with increased drug sales. It also expected operating losses until drug products generated sufficient profits. These expectations depend on commercialization, reimbursement and regulatory progress.
- Other risks include competition and pricing pressure, reimbursement and healthcare policy changes, regulatory and manufacturing compliance, Triferic patent-term uncertainty, and inventory expiration. Auditors gave unqualified opinions on the financial statements and internal controls; management also concluded controls were effective.
Important facts for investors to verify
- CMS decisions and reimbursement treatment for Triferic, plus measurable adoption, sales and inventory usage.
- Calcitriol PAS status, manufacturing stability, launch timing and market uptake.
- Progress and outcome of Baxter arbitration, including exclusivity, disputed receivables, potential refunds and the West Coast facility fee.
- Cash burn, cash and investment balances, inventory reserves and the timing of any path to positive operating cash flow.
- Customer concentration and whether international partners secure approvals and achieve commercial sales or milestone payments.